These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7080043)

  • 1. Factors in cobra venoms affecting the complement system.
    Vogt W
    Toxicon; 1982; 20(1):299-303. PubMed ID: 7080043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function of recombinant cobra venom factor.
    Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
    J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage.
    von Zabern I; Hinsch B; Przyklenk H; Schmidt G; Vogt W
    Immunobiology; 1980 Dec; 157(4-5):499-514. PubMed ID: 6905795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
    Parker CJ; White VF; Falk RJ
    Complement; 1986; 3(4):223-35. PubMed ID: 3643079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of transgenic mice expressing cobra venom factor.
    Andrä J; Halter R; Kock MA; Niemann H; Vogel CW; Paul D
    Mol Immunol; 2002 Oct; 39(5-6):357-65. PubMed ID: 12220893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus.
    Rehana S; Manjunatha Kini R
    Toxicon; 2007 Jul; 50(1):32-52. PubMed ID: 17412383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oligosaccharide chains of cobra venom factor are required for complement activation.
    Grier AH; Vogel CW
    Mol Immunol; 1989 Jun; 26(6):563-74. PubMed ID: 2770749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
    Usami M; Ohno Y
    J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.
    Krishnan V; Ponnuraj K; Xu Y; Macon K; Volanakis JE; Narayana SV
    Structure; 2009 Apr; 17(4):611-9. PubMed ID: 19368894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural studies on the cobra venom factor: isolation, purification, crystallization and preliminary crystallographic analysis.
    Sharma S; Jabeen T; Singh RK; Bredhorst R; Vogel CW; Betzel C; Singh TP
    Acta Crystallogr D Biol Crystallogr; 2001 Apr; 57(Pt 4):596-8. PubMed ID: 11264593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of cobra venom factor on alternative pathway hemolytic activity in mice.
    Joiner KA; Hawiger A; Gelfand JA
    Immunol Commun; 1980; 9(3):277-81. PubMed ID: 7399569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
    Hodgetts SI; Grounds MD
    Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.